替雷利珠单抗治疗MSI-H局部晚期胃癌患者1例 - betway必威登陆网址

国际肿瘤学杂志››2022,Vol. 49››Issue (7): 444-446.doi:10.3760/cma.j.cn371439-20220419-00085

• 病例报道 •上一篇下一篇

替雷利珠单抗治疗MSI-H局部晚期胃癌患者1例

李立立¹(), 安有志², 王艳军¹

1.山东省聊城市第二人民医院肿瘤内科,临清 252600
2.山东省聊城市第二人民医院脊柱外二科,临清 252600

收稿日期:2022-04-19修回日期:2022-06-08出版日期:2022-07-08发布日期:2022-09-19
通讯作者:李立立 E-mail:lili1185459624@163.com

Received:2022-04-19Revised:2022-06-08Online:2022-07-08Published:2022-09-19

摘要/Abstract

摘要：

微卫星高度不稳定型（MSI-H）胃癌临床发病率较低,缺乏系统的诊疗规范,该类型胃癌具有其独特的临床病理学特点,且对免疫检测点抑制剂具有较好的治疗反应,现报道1例局部晚期MSI-H胃癌患者并文献复习,供临床参考。

李立立, 安有志, 王艳军. 替雷利珠单抗治疗MSI-H局部晚期胃癌患者1例[J]. 国际肿瘤学杂志, 2022, 49(7): 444-446.

图/表2

参考文献14

[1]	Ratti M, Lampis A, Hahne JC, et al. Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches[J]. Cell Mol Life Sci, 2018, 75(22): 4151-4162. DOI: 10.1007/s00018-018-2906-9. doi:10.1007/s00018-018-2906-9
[2]	Qu X, Zhao L, Zhang R, et al. Differential microRNA expression profiles associated with microsatellite status reveal possible epige-netic regulation of microsatellite instability in gastric adenocarcinoma[J]. Ann Transl Med, 2020, 8(7): 484. DOI: 10.21037/atm.2020.03.54. doi:10.21037/atm.2020.03.54
[3]	李丹. 环境暴露和错配修复基因多态性单独及联合在胃癌家族性聚集中的作用[D]. 镇江: 江苏大学, 2017: 1-54.
[4]	Kim JW, Cho SY, Chae J, et al. Adjuvant chemotherapy in microsatellite instability-high gastric cancer[J]. Cancer Res Treat, 2020, 52(4): 1178-1187. DOI: 10.4143/crt.2020.313. doi:10.4143/crt.2020.313
[5]	Kim DG, An JY, Kim H, et al. Clinical implications of microsatellite instability in early gastric cancer[J]. J Gastric Cancer, 2019, 19(4): 427-437. DOI: 10.5230/jgc.2019.19.e38. doi:10.5230/jgc.2019.19.e38
[6]	Cai Z, Song H, Fingerhut A, et al. A greater lymph node yield is required during pathological examination in microsatellite instability-high gastric cancer[J]. BMC Cancer, 2021, 21(1): 319. DOI: 10.1186/s12885-021-08044-8. doi:10.1186/s12885-021-08044-8
[7]	Cai Z, Rui W, Li S, et al. Microsatellite status affects tumor response and survival in patients undergoing neoadjuvant chemotherapy for clinical stage Ⅲ gastric cancer[J]. Front Oncol, 2020, 10: 614785. DOI: 10.3389/fonc.2020.614785. doi:10.3389/fonc.2020.614785
[8]	Zepeda-Najar C, Palacios-Astudillo RX, Chávez-Hernández JD, et al. Prognostic impact of microsatellite instability in gastric cancer[J]. Contemp Oncol (Pozn), 2021, 25(1): 68-71. DOI: 10.5114/wo.2021.104939. doi:10.5114/wo.2021.104939
[9]	Lazăr DC, Avram MF, Romosan I, et al. Prognostic significance of tumor immune microenvironment and immunotherapy: novel insights and future perspectives in gastric cancer[J]. World J Gastroenterol, 2018, 24(32): 3583-3616. DOI: 10.3748/wjg.v24.i32.3583. doi:10.3748/wjg.v24.i32.3583
[10]	Wang YL, Gong YH, Lv Z, et al. Expression of PD1/PDL1 in gastric cancer at different microsatellite status and its correlation with infiltrating immune cells in the tumor microenvironment[J]. J Cancer, 2021, 12(6): 1698-1707. DOI: 10.7150/jca.40500. doi:10.7150/jca.40500
[11]	胡广越, 殷红, 张慧, 等. 免疫检查点抑制剂治疗转移性胃癌疗效预测因子[J]. 国际肿瘤学杂志, 2021, 48(8): 498-501. DOI: 10.3760/cma.j.cn371439-20210104-00095. doi:10.3760/cma.j.cn371439-20210104-00095
[12]	An JY, Choi YY, Lee J, et al. A multi-cohort study of the prognostic significance of microsatellite instability or mismatch repair status after recurrence of resectable gastric cancer[J]. Cancer Res Treat, 2020, 52(4): 1153-1161. DOI: 10.4143/crt.2020.173. doi:10.4143/crt.2020.173
[13]	Shen L, Guo J, Zhang Q, et al. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study[J]. J Immunother Cancer, 2020, 8(1): e000437. DOI: 10.1136/jitc-2019-000437. doi:10.1136/jitc-2019-000437
[14]	Jian D, Qian C, Wang D, et al. Conversion therapy with tislelizumab for high microsatellite instability, unresectable stage Ⅲ gastric cancer: a case report[J]. Ann Transl Med, 2021, 9(18): 1489. DOI: 10.21037/atm-21-4295. doi:10.21037/atm-21-4295pmid:34734041

相关文章15

编辑推荐

Metrics

本文评价